arrow
S

Shonali Midha

Dana-Farber Cancer Institute
H指数:15
被引数:800

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Early treatment failure after ciltacabtagene autoleucel in multiple myeloma with high-risk features: implications for risk-informed care

具有高危特征的多发性骨髓瘤在应用cilta-cabtagene autoleucel治疗后早期失败:对风险知情护理的启示

2026-10-220
OAAI
Teclistamab versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trial

Teclistamab 与来那度胺-地塞米松在高风险冒烟型多发性骨髓瘤中的比较:一项随机II期试验

2026-09-110
OAAI
Impact of extramedullary plasmacytoma on outcomes in patients with relapsed refractory multiple myeloma treated with talquetamab: U.S. Myeloma Immunotherapy Consortium
2026-07-270
OA
Isatuximab: an anti-CD38 therapy that addresses unmet needs and mechanisms of resistance in multiple myeloma

伊沙妥昔单抗:一种针对多发性骨髓瘤中未满足需求及耐药机制的抗CD38疗法

2026-05-040
PRE
A review of the clinical efficacy of monoclonal antibody (mAb)-based therapies for relapsed/refractory multiple myeloma (RRMM)

单克隆抗体(mAb)为基础的疗法治疗复发/难治性多发性骨髓瘤(RRMM)的临床疗效综述

2026-04-050
PRE
Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium

elranatamab治疗多发性骨髓瘤的真实世界结局: 来自美国多发性骨髓瘤免疫治疗联盟的多中心分析

2026-03-270
OAAI
The Real-World Safety and Efficacy of Bispecific T-Cell Engager Therapy in Systemic AL Amyloidosis

系统性AL淀粉样变性中双特异性T细胞衔接疗法的安全性与有效性

2025-11-010
PRE
Predictors of Delayed Responses to Teclistamab in Multiple Myeloma After Initial Non-Response

多发性骨髓瘤患者对特克替玛初始无应答后延迟应答的预测因子

2025-10-110
OAAI
Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy

Dhakal, B.; Akhtar, O.S.; Fandrei, D.; Jensen, A.; Banerjee, R.; Pan, D.; Richard, S.; Friend, R.; Rees, M.J.; Costello, P.; 等. 多发性骨髓瘤的序贯靶向治疗:Talquetamab,一种GPRC5D双特异性抗体,作为BCMA CAR-T细胞疗法的桥梁。Blood 2025. [Google Scholar] [CrossRef]

Blood
IF23.1
2025-08-050
PRE
Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the US Multiple Myeloma Immunotherapy Consortium

复发难治性多发性骨髓瘤(RRMM)老年患者接受teclistamab治疗后的结局:一项来自美国多发性骨髓瘤免疫治疗联盟的多中心研究

2025-05-090
OA
Outcomes of Patients By High-Risk Cytogenetic Abnormalities in a Phase II Study of Isatuximab, Weekly Carfilzomib, Lenalidomide, Dexamethasone in Newly Diagnosed, Multiple Myeloma (The SKylaRk Trial) Who Deferred Transplant

伊沙妥昔单抗、每周卡非佐米、来那度胺、地塞米松方案在初诊多发性骨髓瘤患者(SKylaRk试验)中,因延迟移植的高风险细胞遗传学异常患者的结局

BLOOD
IF23.1
2024-11-051
PRE
Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: US Myeloma Immunotherapy Consortium Real- World Experience

接受Idecabtagene Vicleucel治疗的多发性骨髓瘤患者的绝对淋巴细胞计数和结局: 美国骨髓瘤免疫疗法联盟的真实世界经验

2024-08-011
OAAI